We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+0.49%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.58B
AUM Growth
-$476M
(-23%)
Cap. Flow
-$486M
Cap. Flow
% of AUM
-30.8%
Top 10 Holdings %
Top 10 Hldgs %
70.39%
Holding
38
New
4
Increased
7
Reduced
7
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$75.9M |
| 2 |
HCA Healthcare
HCA
|
+$64.3M |
| 3 |
EVHC
Envision Healthcare Holdings Inc
EVHC
|
+$61.3M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
+$49.7M |
| 5 |
RDUS
Radius Health, Inc.
RDUS
|
+$41.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$175M |
| 2 |
Gilead Sciences
GILD
|
+$115M |
| 3 |
AGN
Allergan plc
AGN
|
+$85.1M |
| 4 |
SEM
Select Medical
SEM
|
+$76.8M |
| 5 |
Viatris
VTRS
|
+$52.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 61.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
PTC Therapeutics
PTCT
$6.26B
| – | – |
-500,000
| Closed | -$9.16M |
|
|
SEM
27
DELISTED
Select Medical
SEM
| – | – |
-9,280,000
| Closed | -$76.8M |
|
|
28
CALL
Teva Pharmaceuticals
TEVA
$41.2B
| – | – |
-1,000,000
| Closed | -$33.2M |
|
|
29
Teva Pharmaceuticals
TEVA
$41.2B
| – | – |
-5,266,450
| Closed | -$175M |
|
30
Vertex Pharmaceuticals
VRTX
$122B
| – | – |
-350,000
| Closed | -$45.1M |
|
|
RAD
31
DELISTED
Rite Aid Corporation
RAD
| – | – |
-250,000
| Closed | -$14.8M |
|
|
SIOX
32
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| – | – |
-125,000
| Closed | -$23.2M |
|
|
ENDP
33
DELISTED
Endo International plc
ENDP
| – | – |
-3,574,000
| Closed | -$39.9M |
|
|
ARNA
34
DELISTED
Arena Pharmaceuticals Inc
ARNA
| – | – |
-425,000
| Closed | -$7.17M |
|
|
ALXN
35
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-200,000
| Closed | -$24.3M |
|
|
AGN
36
DELISTED
Allergan plc
AGN
| – | – |
-350,000
| Closed | -$85.1M |
|
|
AVXS
37
DELISTED
AveXis, Inc. Common Stock
AVXS
| – | – |
-210,000
| Closed | -$17.3M |
|
|
ELOS
38
DELISTED
Syneron Medical Ltd
ELOS
| – | – |
-2,347,593
| Closed | -$25.7M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q3 2017 Portfolio in Review
As of Q3 2017, Camber Capital Management held 38 positions worth $1.58B, down 23% from $2.05B the previous quarter. Its ten largest holdings account for 70% of the portfolio.
Camber Capital Management withdrew a net $486M in Q3 2017, closing 15 positions and reducing 7 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $175M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 69% a quarter earlier.
Against the trend, Camber Capital Management opened a new position in Perrigo worth $82.5M.
- Camber Capital Management's largest Q3 2017 buy was Perrigo: 975,000 shares worth $82.5M.
- Camber Capital Management added most to Envision Healthcare Holdings Inc in Q3 2017, an estimated $61.3M increase.
- Camber Capital Management's biggest Q3 2017 reduction was Gilead Sciences, cutting an estimated $115M.
- Camber Capital Management fully exited Teva Pharmaceuticals in Q3 2017, selling an estimated $175M.
- Camber Capital Management's ten largest holdings make up 70% of its $1.58B portfolio in Q3 2017.
- Camber Capital Management opened 4 new positions and closed 15 in Q3 2017.
- Camber Capital Management's portfolio value fell 23% quarter-over-quarter to $1.58B.
Based on Camber Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.